ROCK inhibitors for the treatment of ocular diseases

Ramin Nourinia, shintaro nakao, Souska Zandi, Sare Safi, Ali Hafezi-Moghadam, Hamid Ahmadieh

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The Rho-kinase/ROCK (Rho-associated coiled-coil-containing protein kinase) pathway is involved in the pathogenesis of multiple ocular and systemic disorders. Recently, ROCK inhibitors have been suggested as novel treatments for various ocular diseases. Several in vitro, in vivo and clinical studies have demonstrated the safety and efficacy of ROCK inhibitors in the management of ocular disorders such as corneal epithelial and endothelial damage, glaucoma, retinal and choroidal neovascularisation, diabetic macular oedema and optic nerve disorders. In this review, these studies are explored with focus on the relevant clinical investigations.

Original languageEnglish
JournalBritish Journal of Ophthalmology
Volume102
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Eye Diseases
Retinal Neovascularization
rho-Associated Kinases
Choroidal Neovascularization
Macular Edema
Optic Nerve
Glaucoma
Protein Kinases
Safety
In Vitro Techniques
Clinical Studies

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

ROCK inhibitors for the treatment of ocular diseases. / Nourinia, Ramin; nakao, shintaro; Zandi, Souska; Safi, Sare; Hafezi-Moghadam, Ali; Ahmadieh, Hamid.

In: British Journal of Ophthalmology, Vol. 102, No. 1, 01.01.2018.

Research output: Contribution to journalReview article

Nourinia, Ramin ; nakao, shintaro ; Zandi, Souska ; Safi, Sare ; Hafezi-Moghadam, Ali ; Ahmadieh, Hamid. / ROCK inhibitors for the treatment of ocular diseases. In: British Journal of Ophthalmology. 2018 ; Vol. 102, No. 1.
@article{ad647b9a269a415d8ff3bc4e885158ea,
title = "ROCK inhibitors for the treatment of ocular diseases",
abstract = "The Rho-kinase/ROCK (Rho-associated coiled-coil-containing protein kinase) pathway is involved in the pathogenesis of multiple ocular and systemic disorders. Recently, ROCK inhibitors have been suggested as novel treatments for various ocular diseases. Several in vitro, in vivo and clinical studies have demonstrated the safety and efficacy of ROCK inhibitors in the management of ocular disorders such as corneal epithelial and endothelial damage, glaucoma, retinal and choroidal neovascularisation, diabetic macular oedema and optic nerve disorders. In this review, these studies are explored with focus on the relevant clinical investigations.",
author = "Ramin Nourinia and shintaro nakao and Souska Zandi and Sare Safi and Ali Hafezi-Moghadam and Hamid Ahmadieh",
year = "2018",
month = "1",
day = "1",
doi = "10.1136/bjophthalmol-2017-310378",
language = "English",
volume = "102",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - ROCK inhibitors for the treatment of ocular diseases

AU - Nourinia, Ramin

AU - nakao, shintaro

AU - Zandi, Souska

AU - Safi, Sare

AU - Hafezi-Moghadam, Ali

AU - Ahmadieh, Hamid

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The Rho-kinase/ROCK (Rho-associated coiled-coil-containing protein kinase) pathway is involved in the pathogenesis of multiple ocular and systemic disorders. Recently, ROCK inhibitors have been suggested as novel treatments for various ocular diseases. Several in vitro, in vivo and clinical studies have demonstrated the safety and efficacy of ROCK inhibitors in the management of ocular disorders such as corneal epithelial and endothelial damage, glaucoma, retinal and choroidal neovascularisation, diabetic macular oedema and optic nerve disorders. In this review, these studies are explored with focus on the relevant clinical investigations.

AB - The Rho-kinase/ROCK (Rho-associated coiled-coil-containing protein kinase) pathway is involved in the pathogenesis of multiple ocular and systemic disorders. Recently, ROCK inhibitors have been suggested as novel treatments for various ocular diseases. Several in vitro, in vivo and clinical studies have demonstrated the safety and efficacy of ROCK inhibitors in the management of ocular disorders such as corneal epithelial and endothelial damage, glaucoma, retinal and choroidal neovascularisation, diabetic macular oedema and optic nerve disorders. In this review, these studies are explored with focus on the relevant clinical investigations.

UR - http://www.scopus.com/inward/record.url?scp=85058363185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058363185&partnerID=8YFLogxK

U2 - 10.1136/bjophthalmol-2017-310378

DO - 10.1136/bjophthalmol-2017-310378

M3 - Review article

AN - SCOPUS:85058363185

VL - 102

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 1

ER -